Skip to main content

Tempest Therapeutics’ stock jumps 1,900% as liver-cancer treatment shows promise

The drug candidate showed clinical superiority as a first-line treatment for unresectable or metastatic hepatocellular carcinoma, a common type of liver cancer.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.